Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Children's Hospital Los Angeles)
- Development stage
- Unknown
- Lead developer
- Children's Hospital Los Angeles
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplant (FMT) is an investigational biologic therapy being studied by Children's Hospital Los Angeles for the treatment of pediatric ulcerative colitis. The treatment consists of fecal microbiota sourced from healthy donors, which contains diverse microbial communities intended to correct the gut dysbiosis associated with inflammatory bowel disease. In a Phase 1 clinical trial led by Dr. Sonia Michail, the therapy was administered as a rectal enema to children with mild to moderate ulcerative colitis. The mechanism of action is the modulation and restoration of the gut microbiome, which is considered a key factor in the pathogenesis of the disease. Research from the trial has demonstrated that FMT can lead to sustained increases in gut microbial diversity in these patients. [7] While FMT is approved for recurrent Clostridioides difficile infection, its application in ulcerative colitis is still experimental.
- Other names
- FMTfecal microbiota transplantation
Beyond the preview
Go deeper on fecal microbiota transplant (Children's Hospital Los Angeles).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Children's Hospital Los Angeles).